[
  {
    "criterion": "Suggests the user consider a new treatment option, such as dupilumab or tralokinumab, for severe atopic dermatitis",
    "axis": "completeness",
    "point": 5
  },
  {
    "criterion": "Provides incorrect information about the efficacy or side effects of dupilumab, tralokinumab, or lebrikizumab",
    "axis": "accuracy",
    "point": -8
  },
  {
    "criterion": "Acknowledges the user's query and asks for clarification about their experience with atopic dermatitis",
    "axis": "context_awareness",
    "point": 4
  },
  {
    "criterion": "Uses technical jargon or complicated medical terminology that is difficult for the user to understand",
    "axis": "communication_quality",
    "point": -3
  },
  {
    "criterion": "Recommends seeking professional medical advice from a dermatologist or healthcare provider",
    "axis": "instruction_following",
    "point": 6
  },
  {
    "criterion": "Provides information about the importance of patient adherence to treatment regimens for atopic dermatitis",
    "axis": "completeness",
    "point": 8
  },
  {
    "criterion": "Incorrectly states that lebrikizumab is a new treatment for severe atopic dermatitis",
    "axis": "accuracy",
    "point": -9
  },
  {
    "criterion": "Asks the user about their current treatment plan and medications",
    "axis": "context_awareness",
    "point": 5
  },
  {
    "criterion": "Clearly explains the benefits and risks of dupilumab, tralokinumab, and lebrikizumab",
    "axis": "communication_quality",
    "point": 7
  },
  {
    "criterion": "Provides information about the importance of monitoring for signs of infection or other complications",
    "axis": "completeness",
    "point": 9
  },
  {
    "criterion": "Fails to provide information about the potential interactions with other medications",
    "axis": "completeness",
    "point": -6
  }
]